0001209191-18-016866.txt : 20180305
0001209191-18-016866.hdr.sgml : 20180305
20180305183940
ACCESSION NUMBER: 0001209191-18-016866
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180301
FILED AS OF DATE: 20180305
DATE AS OF CHANGE: 20180305
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Herberts Curt A. III
CENTRAL INDEX KEY: 0001691262
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30171
FILM NUMBER: 18668052
MAIL ADDRESS:
STREET 1: 501 CANAL BLVD.
STREET 2: POINT RICHMOND TECH CENTER
CITY: RICHMOND
STATE: CA
ZIP: 94804
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SANGAMO THERAPEUTICS, INC
CENTRAL INDEX KEY: 0001001233
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 680359556
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 501 CANAL BLVD
STREET 2: POINT RICHMOND TECH CNTR.
CITY: RICHMOND
STATE: CA
ZIP: 94804
BUSINESS PHONE: 5109706000
MAIL ADDRESS:
STREET 1: 501 CANAL BLVD
STREET 2: POINT RICHMOND TECH CNTR.
CITY: RICHMOND
STATE: CA
ZIP: 94804
FORMER COMPANY:
FORMER CONFORMED NAME: SANGAMO BIOSCIENCES INC
DATE OF NAME CHANGE: 20000208
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-03-01
0
0001001233
SANGAMO THERAPEUTICS, INC
SGMO
0001691262
Herberts Curt A. III
C/O SANGAMO THERAPEUTICS, INC.
POINT RICHMOND TECH CTR, 501 CANAL BLVD.
RICHMOND
CA
94804
0
1
0
0
Sr.VP & Chief Business Officer
Common Stock
2018-03-01
4
M
0
171
12.12
A
14796
D
Common Stock
2018-03-01
4
M
0
1430
9.41
A
16226
D
Common Stock
2018-03-01
4
M
0
8087
14.07
A
24313
D
Common Stock
2018-03-01
4
M
0
5312
3.50
A
29625
D
Common Stock
2018-03-01
4
S
0
15000
23.0574
D
14625
D
Stock Option (Right to Buy)
12.12
2018-03-01
4
M
0
171
0.00
D
2023-12-11
Common Stock
171
0
D
Stock Option (Right to Buy)
14.07
2018-03-01
4
M
0
8087
0.00
D
2024-12-10
Common Stock
8087
11913
D
Stock Option (Right to Buy)
9.41
2018-03-01
4
M
0
1430
0.00
D
2025-12-07
Common Stock
1430
17320
D
Stock Option (Right to Buy)
3.50
2018-03-01
4
M
0
5312
0.00
D
2027-01-25
Common Stock
5312
54688
D
All sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2017.
The price reported is a weighted average price. The shares were sold at prices ranging from $22.60 to $23.60 The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
Includes (a) 8,375 shares subject to restricted stock units granted on January 24, 2018 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such date; and (b) 6,250 shares subject to restricted stock units granted on December 8, 2015 that will vest on December 8, 2018, subject to the Reporting Person's continued service with the Issuer through such date.
Fully vested and exercisable.
One-quarter (1/4) of the option shares vested and became exercisable upon completion of one (1) year of service by the Reporting Person measured from the December 11, 2014 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.
One-quarter (1/4) of the option shares vested and became exercisable upon completion of one (1) year of service by the Reporting Person measured from the December 8, 2015 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.
The stock option vested and became exercisable for 25% of the shares upon the Reporting Person's completion of one year of service measured from the January 26, 2017 grant date, and the balance of the shares will vest and become exercisable in 36 successive equal monthly installments upon his completion of each additional month of service thereafter.
/s/ Denise Winn, Attorney-in-Fact
2018-03-05